SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-22-005412
Filing Date
2022-01-19
Accepted
2022-01-19 16:01:18
Documents
1
Period of Report
2022-01-18

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm223320-3_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm223320-3_4seq1.xml 4 3379
  Complete submission text file 0001104659-22-005412.txt   4845
Mailing Address C/O ARBUTUS BIOPHARMA 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address
HASTINGS DAVID C (Reporting) CIK: 0001237401 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38670 | Film No.: 22538720

Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Issuer) CIK: 0001724344 (see all company filings)

IRS No.: 824592913 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations